Journal of Bone and Mineral Metabolism

, Volume 23, Issue 5, pp 382–388 | Cite as

Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study

  • Shinji Uchida
  • Tadaaki Taniguchi
  • Takafumi Shimizu
  • Taro Kakikawa
  • Kotoba Okuyama
  • Masahiko Okaniwa
  • Hironori Arizono
  • Koichi Nagata
  • Arthur C. Santora
  • Masataka Shiraki
  • Masao Fukunaga
  • Tatsushi Tomomitsu
  • Yasuo Ohashi
  • Toshitaka Nakamura
ORIGINAL ARTICLE

Abstract

The efficacy and safety of treatment with oral alendronate (ALN) 35 mg once weekly for 52 weeks were compared with those of ALN 5 mg once daily in a double-blind, randomized, multicenter study of Japanese patients with involutional osteoporosis. The primary efficacy end point was the percent change from baseline in the lumbar spine (L1–L4) bone mineral density (BMD) after 52 weeks of treatment. In this study, 328 patients were randomized to ALN 5 mg once daily (160 patients) or ALN 35 mg once weekly (168 patients). The adjusted mean percent change from baseline in lumbar spine (L1–L4) BMD after 52 weeks of treatment was 5.8% and 6.4% in the once-daily group and the once-weekly group, respectively (both P < 0.001). The 95% confidence interval for the difference in spine BMD change between the two treatment groups was −0.31% to 1.48%, indicating that the two regimens were therapeutically equivalent, since the confidence interval fell entirely within the predefined equivalence criterion (±1.5%). The time course of the spine BMD increase was also similar for both regimens. Regarding total hip BMD, mean changes from baseline at 52 weeks were 2.8% and 3.0% in the once-daily group and the once-weekly group, respectively. In addition, the bone markers (urinary deoxypyridinoline, urinary type-I collagen N-telopeptides, and serum bone-specific alkaline phosphatase) were reduced to a similar level by either treatment throughout the treatment period. The tolerability and safety profiles were also similar between the treatment groups. Taken together, we conclude that the efficacy and safety of the ALN 35-mg once-weekly regimen are therapeutically equivalent to those of the ALN 5-mg once-daily regimen.

Key words

Alendronate Involutional osteoporosis Bone markers BMD 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Consensus Development Conference1993Diagnosis, prophylaxis, and treatment of osteoporosisAm J Med94646650Google Scholar
  2. 2.
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy2001Osteoporosis prevention, diagnosis, and therapyJAMA285785795Google Scholar
  3. 3.
    Japan Osteoporosis Society Working Group2002Guideline to Clinical Evaluation Methods for Agents Used in Treatment of Osteoporosis, 2002 Revised Edition (in Japanese)Osteoporos Jpn10779Google Scholar
  4. 4.
    Fujiwara, S, Kasagi, F, Masunari, N, Naito, K, Suzuki, G, Fukunaga, M 2003Fracture prediction from bone mineral density in Japanese men and womenJ Bone Miner Res1815471553PubMedGoogle Scholar
  5. 5.
    Black, DM, Cummings, SR, Karpf, DB, Cauley, JA, Thompson, DE, Nevitt, MC, Bauer, DC, Genant, HK, Haskell, WL, Marcus, R, Ott, SM, Torner, JC, Quandt, SA, Reiss, TF, Ensrud, KE 1996Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet34815351541PubMedGoogle Scholar
  6. 6.
    Cummings, SR, Black, DM, Thompson, DE, Applegate, WB, Barrett-Connor, E, Musliner, TA, Palermo, L, Prineas, R, Rubin, SM, Scott, JC, Vogt, T, Wallace, R, Yates, AJ, LaCroix, AZ 1998Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trialJAMA28020772082CrossRefPubMedGoogle Scholar
  7. 7.
    Liberman, UA, Weiss, SR, Broll, J, Minne, HW, Quan, H, Bell, NH, Rodriguez-Portales, J, Downs, RW,Jr, Dequeker, J, Favus, M, Seeman, E, Recker, RR, Capizzi, T, Santora, ACII, Lombardi, A, Shah, RV, Hirsch, LJ, Karpf, DB 1995Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisN Engl J Med33314371443CrossRefGoogle Scholar
  8. 8.
    Tucci, JR, Tonino, RP, Emkey, RD, Peverly, CA, Kher, U, Santora , AC,II 1996Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosisAm J Med101488501CrossRefPubMedGoogle Scholar
  9. 9.
    Devogelaer, JP, Broll, H, Correa-Rotter, R, Cumming, DC, Nagant de Deuxchaisnes, C,  et al. 1996Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisBone18141150CrossRefPubMedGoogle Scholar
  10. 10.
    Karpf, DB, Shapiro, DR, Seeman, E, Ensrud, KE, Johnston, CC,Jr, Adami, S, Harris, ST, Santora, ACII, Hirsch, LJ, Oppenheimer, L, Thompson, D 1997Prevention of nonvertebral fractures by alendronate. A meta-analysisJAMA27711591164CrossRefPubMedGoogle Scholar
  11. 11.
    Sharpe, M, Noble, S, Spencer, CM 2001Alendronate: an update of its use in osteoporosisDrugs619991039PubMedGoogle Scholar
  12. 12.
    Cranney, A, Wells, G, Willan, A, Griffith, L, Zytaruk, N, Robinson, V, Black, D, Adachi, J, Shea, B, Tugwell, P, Guyatt, G 2002II. Meta-analysis of alendronate for the treatment of postmenopausal womenEndocr Rev23508516CrossRefPubMedGoogle Scholar
  13. 13.
    Tonino, RP, Meunier, PJ, Emkey, R, Rodriguez-Portales, JA, Menkes, CJ, Wasnich, RD, Bone, HG, Santora, AC, Wu, M, Desai, R, Ross, PD 2000Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study GroupJ Clin Endocrinol Metab8531093115CrossRefPubMedGoogle Scholar
  14. 14.
    Pols, HA, Felsenberg, D, Hanley, DA, Stepán, J, Muñoz-Torres, M, Wilkin, TJ, Qin-sheng, G, Galich, AM, Vandormael, K, Yates, AJ, Stych, B 1999Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT studyOsteoporos Int9461468PubMedGoogle Scholar
  15. 15.
    Black, DM, Thompson, DE, Bauer, DC, Ensrud, K, Musliner, T, Hochberg, MC, Nevitt, MC, Suryawanshi, S, Cummings, SR 2000Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trialJ Clin Endocrinol Metab8541184124CrossRefPubMedGoogle Scholar
  16. 16.
    Bone, HG, Hosking, D, Devogelaer, JP, Tucci, JR, Emkey, RD, Tonino, RP, Rodriguez-Portales, JA, Downs, RW, Gupta, J, Santora, AC, Liberman, UA 2004Ten years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med35011891199CrossRefPubMedGoogle Scholar
  17. 17.
    Wehren, LE, Hosking, D, Hochberg, MC 2004Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosisCurr Med Res Opin20525531CrossRefPubMedGoogle Scholar
  18. 18.
    Shiraki, M, Kushida, K, Fukunaga, M, Kishimoto, H, Kaneda, K, Minaguchi, H, Inoue, T, Tomita, A, Nagata, Y, Nakashima, M, Orimo, H 1998A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosisEndocr J45191201PubMedGoogle Scholar
  19. 19.
    Nakamura, T, Kushida, K, Shiraki, M, Fukunaga, M, Taga, M, Kishimoto, H, Tomita, A, Inoue, T, Minaguchi, H, Kaneda, K, Nagata, Y, Nakashima, M, Orimo, H 1998A double-blind, dose-ranging study of alendronate in patients with involutional osteoporosis, osteoporotic osteopenia or artificial menopause (in Japanese)Med Consult New Remedy35317Google Scholar
  20. 20.
    Kishimoto, H, Shiraki, M, Fukunaga, M, Kushida, K, Kaneda, K, Inoue, T, Tomita, A, Yamamoto, K, Orimo, H 1998A long-term study of alendronate in patients with involutional osteoporosis (in Japanese)Med Consult New Remedy351941Google Scholar
  21. 21.
    Shiraki, M, Kushida, K, Fukunaga, M, Kishimoto, H, Taga, M, Nakamura, T, Kaneda, K, Minaguchi, H, Inoue, T, Morii, H, Tomita, A, Yamamoto, K, Nagata, Y, Nakashima, M, Orimo, H 1999A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosisOsteoporos Int10183192CrossRefPubMedGoogle Scholar
  22. 22.
    Kushida, K, Shiraki, M, Nakamura, T, Kishimoto, H, Morii, H, Yamamoto, K, Kaneda, K, Fukunaga, M, Inoue, T, Nakashima, M, Orimo, H 2002The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trialCurr Ther Res63606620CrossRefGoogle Scholar
  23. 23.
    Kushida, K, Shiraki, M, Nakamura, T, Kishimoto, H, Morii, H, Yamamoto, K, Kaneda, K, Fukunaga, M, Inoue, T, Nakashima, M, Orimo, H 2004Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up studyJ Bone Miner Metab22462468CrossRefPubMedGoogle Scholar
  24. 24.
    Schnitzer, T, Bone, HG, Crepaldi, G, Adami, S, McClung, M,  et al. 2000Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosisAging Clin Exp Res12112Google Scholar
  25. 25.
    Rizzoli, R, Greenspan, SL, Bone, H,III, Schnitzer, TJ, Watts, NB, Adami, S, Foldes, AJ, Roux, C, Levine, MA, Uebelhart, B, Santora, AC,II, Kaur, A, Peverly, CA, Orloff, JJ 2002Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisJ Bone Miner Res1719881996PubMedGoogle Scholar
  26. 26.
    Naruse, S, Kato, Y, Tani, K, Hisaka, A, Watanabe, H, Arizono, H, Taniguchi, T 2004Pharmacokinetic study of alendronate in postmenopausal Japanese women – Evaluation of urinary excretion and safety profile of alendronate after single oral administration of 35 mg and 5 mg tablet formulations (in Japanese)Rinsyo Iyaku2018Google Scholar
  27. 27.
    Greenberg, RN 1984Overview of patient compliance with medication dosing: a literature reviewClin Ther6592599PubMedGoogle Scholar
  28. 28.
    Bone, HG, Adami, S, Rizzoli, R, Favus, M, Ross, PD, Santora, A, Prahalada, S, Daifotis, A, Orloff, J, Yates, J 2000Weekly administration of alendronate: rationale and plan for clinical assessmentClin Ther221528CrossRefPubMedGoogle Scholar
  29. 29.
    Lanza, F, Sahba, B, Schwartz, H, Winograd, S, Torosis, J, Quan, H, Reyes, R, Musliner, T, Daifotis, A, Leung, A 2002The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy studyAm J Gastroenterol975864CrossRefPubMedGoogle Scholar
  30. 30.
    Greenspan, S, Field-Munves, E, Tonino, R, Smith, M, Petruschke, R, Wang, L, Yates, J, DePapp, AE, Palmisano, J 2002Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled studyMayo Clin Proc7710441052PubMedGoogle Scholar
  31. 31.
    Cryer, B, Bauer, DC 2002Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clin Proc7710311043PubMedGoogle Scholar
  32. 32.
    Simon, JA, Lewiecki, EM, Smith, ME, Petruschke, RA, Wang, L, Palmisano, JJ 2002Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover studyClin Ther2418711886CrossRefPubMedGoogle Scholar
  33. 33.
    Kendler, D, Kung, AWC, Fuleihan, GEH, Gonzalez, JGG, Gaines, KA, Verbruggen, N, Melton, ME 2004Patients with osteoporosis prefer once weekly to once daily dosing with alendronateEur Menopause J48243251Google Scholar

Copyright information

© Springer-Verlag Tokyo 2005

Authors and Affiliations

  • Shinji Uchida
    • 1
  • Tadaaki Taniguchi
    • 1
  • Takafumi Shimizu
    • 1
  • Taro Kakikawa
    • 1
  • Kotoba Okuyama
    • 1
  • Masahiko Okaniwa
    • 2
  • Hironori Arizono
    • 2
  • Koichi Nagata
    • 2
  • Arthur C. Santora
    • 3
  • Masataka Shiraki
    • 4
  • Masao Fukunaga
    • 5
  • Tatsushi Tomomitsu
    • 5
  • Yasuo Ohashi
    • 6
  • Toshitaka Nakamura
    • 7
  1. 1.Clinical Development InstituteBanyu Pharmaceutical Co., Ltd.TokyoJapan
  2. 2.Pharmaceutical Business UnitTeijin Pharma Ltd.TokyoJapan
  3. 3.Merck Research LaboratoriesRahwayUSA
  4. 4.Research Institute and Practice for Involutional DiseasesNaganoJapan
  5. 5.Kawasaki Medical SchoolOkayamaJapan
  6. 6.Biostatistics, University of TokyoTokyoJapan
  7. 7.University of Occupational and Environmental HealthFukuokaJapan

Personalised recommendations